Search 

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3(R)) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry.

C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294m.

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO.

Operating from state-of-the-art research facilities in Loughborough and BioCity Nottingham, UK, we are a leading Contract Research Organisation, providing medicinal and synthetic chemistry services to the global pharmaceutical, biotechnology and chemical industries.

The cornerstone of our success is built upon regular and open communication with our clients, the highest integrity in our business relationships, high quality yet cost effective services, and the flexibility that we offer – we can undertake projects from one week in duration to multi-year, multi-FTE collaborations. Our goal is to support you in producing excellence in your own research, achieving your milestones and business objectives on time and to budget.

We offer a range of competitively priced services tailored to the specific requirements of our clients. These include Medicinal Chemistry and Contract Research (FTE). 

Medicinal Chemistry
Charnwood Molecular offers support to drug discovery efforts within the pharmaceutical and biotechnology industries. This service covers Lead Discovery and Lead Optimisation. Our pharma-trained medicinal chemists have experience in many therapeutic areas.

Contract Research
Presented with a target molecule with little or no literature precedent, we will investigate potential methods of preparation, optimisation and scale-up, according to your needs.

Crystec Pharma is focused on applying supercritical fluid technology to improve the performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.

Applications of our mSAS® (modified Supercritical Anti-Solvent) technology include enhancing the dissolution and bioavailability of drugs, optimising release profiles, as well as improving stability and processing characteristics.

Our solutions include the following:

• Crystal and particle engineering

• Stabilisation of therapeutic agents derived from biotechnology

• Polymorph screening

• Improved performance of poorly soluble drugs

• Improved bioavailabilty of small molecules

• Alternative routes of delivery such as inhaled therapy

• Taste masking

• Crystallisation seeds

• Residual solvent elimination